

Sören Måller

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2243446/publications.pdf>

Version: 2024-02-01

155
papers

5,475
citations

76031

42
h-index

111975

67
g-index

161
all docs

161
docs citations

161
times ranked

4945
citing authors

#	ARTICLE	IF	CITATIONS
1	Colonic Lactulose Fermentation Has No Impact on Glucagon-like Peptide-1 and Peptide-YY Secretion in Healthy Young Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 77-87.	1.8	6
2	Patients With Cirrhosis Have Elevated Bone Turnover but Normal Hepatic Production of Osteoprotegerin. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e980-e995.	1.8	4
3	Dipeptidyl peptidase-3 is associated with severity of liver disease and circulatory complications in patients with cirrhosis. <i>Biomarkers</i> , 2022, 27, 196-204.	0.9	3
4	Determination of hepatic clearance by derivations of the indocyanine green retention test in cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 692-699.	1.4	0
5	Granular clinical history and outcome in 51 patients with primary and secondary malignant meningioma. <i>Journal of Neurosurgery</i> , 2022, 137, 1347-1357.	0.9	4
6	Long-term changes of pancreatic function in patients with complicated walled-off necrosis. <i>Scandinavian Journal of Gastroenterology</i> , 2022, , 1-7.	0.6	0
7	Indications and methods for measuring portal hypertension in cirrhosis. <i>Scandinavian Journal of Gastroenterology</i> , 2022, 57, 1149-1157.	0.6	2
8	Cirrhotic cardiomyopathy: Toward an optimized definition. <i>Liver Transplantation</i> , 2022, 28, 1283-1284.	1.3	1
9	Blunted cardiovascular effects of beta-blockers in patients with cirrhosis: Relation to severity?. <i>PLoS ONE</i> , 2022, 17, e0270603.	1.1	2
10	Systemic inflammation is linked to liver fibrogenesis in patients with advanced chronic liver disease. <i>Liver International</i> , 2022, 42, 2501-2512.	1.9	16
11	Differential inflammasome activation predisposes to acute-on-chronic liver failure in human and experimental cirrhosis with and without previous decompensation. <i>Gut</i> , 2021, 70, gutjnl-2019-320170.	6.1	47
12	Possible Relevance of Soluble Luteinizing Hormone Receptor during Development and Adulthood in Boys and Men. <i>Cancers</i> , 2021, 13, 1329.	1.7	1
13	Prolonged QT-interval in cirrhosis: is it reversible?. <i>International Journal of Cardiology</i> , 2021, 329, 113-114.	0.8	1
14	Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: Overlapping Mechanisms. <i>Seminars in Liver Disease</i> , 2021, 41, 235-247.	1.8	4
15	Arm lean mass determined by dual-energy X-ray absorptiometry is superior to characterize skeletal muscle and predict sarcopenia-related mortality in cirrhosis. <i>American Journal of Physiology - Renal Physiology</i> , 2021, 320, G729-G740.	1.6	10
16	Using MR elastography to assess portal hypertension and response to beta-blockers in patients with cirrhosis. <i>Liver International</i> , 2021, 41, 2149-2158.	1.9	15
17	Divergences in Macrophage Activation Markers Soluble CD163 and Mannose Receptor in Patients With Non-cirrhotic and Cirrhotic Portal Hypertension. <i>Frontiers in Physiology</i> , 2021, 12, 649668.	1.3	4
18	Progressive alcohol-related liver fibrosis is characterised by imbalanced collagen formation and degradation. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 1070-1080.	1.9	22

#	ARTICLE	IF	CITATIONS
19	Novel Anti-inflammatory Treatments in Cirrhosis. A Literature-Based Study. <i>Frontiers in Medicine</i> , 2021, 8, 718896.	1.2	7
20	Pathophysiology Behind Cardiopulmonary Complications of Cirrhosis and Portal Hypertension. , 2021, , 43-72.		0
21	Energy expenditure and loss of muscle and fat mass in patients with walled-off pancreatic necrosis: A prospective study. <i>Nutrition</i> , 2020, 69, 110574.	1.1	3
22	Dobutamine reverses the cardio-suppressive effects of terlipressin without improving renal function in cirrhosis and ascites: a randomized controlled trial. <i>American Journal of Physiology - Renal Physiology</i> , 2020, 318, G313-G321.	1.6	10
23	Mechanisms in fluid retention “ towards a mutual concept. <i>Clinical Physiology and Functional Imaging</i> , 2020, 40, 67-75.	0.5	3
24	Pituitary adenylate cyclase-activating peptide: Potential roles in the pathophysiology and complications of cirrhosis. <i>Liver International</i> , 2020, 40, 2578-2589.	1.9	2
25	Fibrogenesis and inflammation contribute to the pathogenesis of cirrhotic cardiomyopathy. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 340-350.	1.9	16
26	Pathophysiological-based treatments of complications of cirrhosis. <i>Scandinavian Journal of Gastroenterology</i> , 2020, 55, 383-394.	0.6	6
27	Cardiodynamic state is associated with systemic inflammation and fatal acute-chronic liver failure. <i>Liver International</i> , 2020, 40, 1457-1466.	1.9	46
28	Left atrial volume changes assessed by real time 3-dimensional echocardiography in relation to liver function and prognosis in patients with cirrhosis. <i>International Journal of Cardiovascular Imaging</i> , 2020, 36, 2121-2127.	0.7	10
29	Kinetics of the soluble urokinase plasminogen activator receptor (suPAR) in cirrhosis. <i>PLoS ONE</i> , 2019, 14, e0220697.	1.1	5
30	Recurrent glioblastoma versus late posttreatment changes: diagnostic accuracy of O-(2-[18F]fluoroethyl)-L-tyrosine positron emission tomography (18F-FET PET). <i>Neuro-Oncology</i> , 2019, 21, 1595-1606.	0.6	37
31	Cardiac dysfunction in cirrhosis: a 2-yr longitudinal follow-up study using advanced cardiac imaging. <i>American Journal of Physiology - Renal Physiology</i> , 2019, 317, G253-G263.	1.6	19
32	Minimally invasive assessment of hepatic function in children with indocyanine green elimination: a validation study. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 485-491.	0.6	2
33	Collagen type IV remodelling gender-specifically predicts mortality in decompensated cirrhosis. <i>Liver International</i> , 2019, 39, 885-893.	1.9	26
34	An update on cirrhotic cardiomyopathy. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 497-505.	1.4	33
35	Enhanced processing of von Willebrand factor reflects disease severity and discriminates severe portal hypertension in cirrhosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 1040-1048.	0.8	2
36	Indocyanine green retention test in cirrhosis and portal hypertension: Accuracy and relation to severity of disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 1093-1099.	1.4	22

#	ARTICLE	IF	CITATIONS
37	Acute decompensation boosts hepatic collagen type III deposition and deteriorates experimental and human cirrhosis. <i>Hepatology Communications</i> , 2018, 2, 211-222.	2.0	45
38	Pronounced Coronary Arteriosclerosis in Cirrhosis: Influence on Cardiac Function and Survival?. <i>Digestive Diseases and Sciences</i> , 2018, 63, 1355-1362.	1.1	8
39	Total bile acid levels are associated with left atrial volume and cardiac output in patients with cirrhosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 392-397.	0.8	13
40	Cirrhotic cardiomyopathy. <i>Journal of Hepatology</i> , 2018, 69, 958-960.	1.8	58
41	Validation of noninvasive haemodynamic methods in patients with liver disease: the Finometer and the Task Force Monitor. <i>Clinical Physiology and Functional Imaging</i> , 2018, 38, 384-389.	0.5	11
42	Rifaximin has minor effects on bacterial composition, inflammation, and bacterial translocation in cirrhosis: A randomized trial. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 307-314.	1.4	51
43	Transjugular intrahepatic portosystemic shunt: impact on systemic hemodynamics and renal and cardiac function in patients with cirrhosis. <i>American Journal of Physiology - Renal Physiology</i> , 2018, 314, G275-G286.	1.6	44
44	The pathophysiology of arterial vasodilatation and hyperdynamic circulation in cirrhosis. <i>Liver International</i> , 2018, 38, 570-580.	1.9	136
45	No effect of rifaximin on soluble CD163, mannose receptor or type III and IV neopeptide collagen markers in decompensated cirrhosis: Results from a randomized, placebo controlled trial. <i>PLoS ONE</i> , 2018, 13, e0203200.	1.1	6
46	Myocardial extracellular volume quantified by magnetic resonance is increased in cirrhosis and related to poor outcome. <i>Liver International</i> , 2018, 38, 1614-1623.	1.9	30
47	Cardiac imaging in patients with chronic liver disease. <i>Clinical Physiology and Functional Imaging</i> , 2017, 37, 347-356.	0.5	16
48	Bile acids and cardiovascular function in cirrhosis. <i>Liver International</i> , 2017, 37, 1420-1430.	1.9	44
49	Selective imaging modalities after first pyelonephritis failed to identify significant urological anomalies, despite normal antenatal ultrasounds. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2017, 106, 1176-1183.	0.7	5
50	Assessment of systolic function in the evaluation of patients with cirrhosis. <i>Hepatology</i> , 2017, 65, 1799-1802.	3.6	8
51	The royal free hospital cirrhosis glomerular filtration rate: Validation in a danish cohort. <i>Hepatology</i> , 2017, 66, 1360-1361.	3.6	3
52	Cardiovascular Effects of a Transjugular Intrahepatic Portosystemic Shunt in Patients with Cirrhosis. <i>Current Hepatology Reports</i> , 2017, 16, 250-257.	0.4	0
53	Effects of transjugular intrahepatic portosystemic shunt (TIPS) on blood volume distribution in patients with cirrhosis. <i>Digestive and Liver Disease</i> , 2017, 49, 1353-1359.	0.4	24
54	Rifaximin has no effect on hemodynamics in decompensated cirrhosis: A randomized, double-blind, placebo-controlled trial. <i>Hepatology</i> , 2017, 65, 592-603.	3.6	60

#	ARTICLE	IF	CITATIONS
55	Aquaporinâ€2 excretion in hospitalized patients with cirrhosis: Relation to development of renal insufficiency and mortality. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1087-1093.	1.4	3
56	Neutrophil gelatinaseâ€associated lipocalin and cystatin C in cirrhosis and portal hypertension: Relations to organ extraction and dysfunction. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 473-481.	1.4	5
57	The soluble mannose receptor (sMR) is elevated in alcoholic liver disease and associated with disease severity, portal hypertension, and mortality in cirrhosis patients. <i>PLoS ONE</i> , 2017, 12, e0189345.	1.1	32
58	Toward new standards for noninvasive measuring of portal pressure?. <i>Hepatology</i> , 2016, 63, 1384-1386.	3.6	0
59	Diastolic dysfunction in cirrhosis. <i>Heart Failure Reviews</i> , 2016, 21, 599-610.	1.7	28
60	Research update for articles published in <sc>EJCI</sc> in 2014. <i>European Journal of Clinical Investigation</i> , 2016, 46, 880-894.	1.7	2
61	Indocyanine green retention test (ICG-r15) as a noninvasive predictor of portal hypertension in patients with different severity of cirrhosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 948-954.	0.8	31
62	Hepatorenal syndrome in cirrhosis: diagnostic, pathophysiological, and therapeutic aspects. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 1153-1161.	1.4	15
63	Plasma ADAMTS-13 protein is not associated with portal hypertension or hemodynamic changes in patients with cirrhosis. <i>Digestive and Liver Disease</i> , 2016, 48, 404-408.	0.4	6
64	Assessment of response to beta-blockers by expression of β^2 Arr2 and RhoA/ROCK2 in antrum mucosa in cirrhotic patients. <i>Journal of Hepatology</i> , 2016, 64, 1265-1273.	1.8	27
65	Hepatic erythropoietin response in cirrhosis. A contemporary review. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2016, 76, 183-189.	0.6	5
66	Hepatic erythropoietin response in cirrhosis. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2016, 76, 234-239.	0.6	5
67	Cardiac Biomarkers in Cirrhosis and Portal Hypertension: Relation to Circulatory and Cardiac Dysfunction. , 2016, , 573-599.		7
68	Acidâ€base disturbance in patients with cirrhosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2015, 27, 920-927.	0.8	17
69	Pro-C5, a marker of true type V collagen formation and fibrillation, correlates with portal hypertension in patients with alcoholic cirrhosis. <i>Scandinavian Journal of Gastroenterology</i> , 2015, 50, 584-592.	0.6	43
70	Immunologic, hemodynamic, and adrenal incompetence in cirrhosis: impact on renal dysfunction. <i>Hepatology International</i> , 2015, 9, 17-27.	1.9	8
71	Cirrhotic Multiorgan Syndrome. <i>Digestive Diseases and Sciences</i> , 2015, 60, 3209-3225.	1.1	35
72	Cardiovascular complications of NAFLDâ€they do matter. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2015, 12, 434-436.	8.2	3

#	ARTICLE	IF	CITATIONS
73	Complications of cirrhosis. A 50 years flashback. <i>Scandinavian Journal of Gastroenterology</i> , 2015, 50, 763-780.	0.6	19
74	Management of cirrhotic ascites. <i>Therapeutic Advances in Chronic Disease</i> , 2015, 6, 124-137.	1.1	55
75	Beta-blockers in cirrhosis and refractory ascites: a retrospective cohort study and review of the literature. <i>Scandinavian Journal of Gastroenterology</i> , 2015, 50, 129-137.	0.6	34
76	Cardiac Biomarkers in Cirrhosis and Portal Hypertension: Relation to Circulatory and Cardiac Dysfunction. , 2015, , 1-27.		0
77	PRO-C3-Levels in Patients with HIV/HCV-Co-Infection Reflect Fibrosis Stage and Degree of Portal Hypertension. <i>PLoS ONE</i> , 2014, 9, e108544.	1.1	29
78	Assessment of diastolic function in the management of patients with cirrhosis. <i>Hepatology International</i> , 2014, 8, 472-474.	1.9	2
79	TIMP-1 in patients with cirrhosis: relation to liver dysfunction, portal hypertension, and hemodynamic changes. <i>Scandinavian Journal of Gastroenterology</i> , 2014, 49, 1103-1110.	0.6	23
80	Variceal Rebleeding: Drugs, Endoscopy or Both. , 2014, , 213-228.		2
81	Diastolic and autonomic dysfunction in early cirrhosis: a dobutamine stress study. <i>Scandinavian Journal of Gastroenterology</i> , 2014, 49, 362-372.	0.6	22
82	Combined antiretroviral therapy attenuates hepatic extracellular matrix remodeling in HIV patients assessed by novel protein fingerprint markers. <i>Aids</i> , 2014, 28, 2081-2090.	1.0	24
83	Association of markers of bacterial translocation with immune activation in decompensated cirrhosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2014, 26, 1360-1366.	0.8	21
84	Kidney injury in cirrhosis: pathophysiological and therapeutic aspects of hepatorenal syndromes. <i>Liver International</i> , 2014, 34, 1153-1163.	1.9	40
85	Effects of carvedilol and propranolol on circulatory regulation and oxygenation in cirrhosis: A randomised study. <i>Digestive and Liver Disease</i> , 2014, 46, 251-256.	0.4	19
86	New vasoactive peptides in cirrhosis: organ extraction and relation to the vasodilatory state. <i>European Journal of Clinical Investigation</i> , 2014, 44, 441-452.	1.7	24
87	Cardiac and proinflammatory markers predict prognosis in cirrhosis. <i>Liver International</i> , 2014, 34, e19-30.	1.9	65
88	Cirrhotic cardiomyopathy: pathogenesis and clinical relevance. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2014, 11, 177-186.	8.2	205
89	Cardiac Function in Patients with Early Cirrhosis during Maximal Beta-Adrenergic Drive: A Dobutamine Stress Study. <i>PLoS ONE</i> , 2014, 9, e109179.	1.1	15
90	Extrahepatic complications to cirrhosis and portal hypertension: Haemodynamic and homeostatic aspects. <i>World Journal of Gastroenterology</i> , 2014, 20, 15499.	1.4	62

#	ARTICLE	IF	CITATIONS
91	New insights into cirrhotic cardiomyopathy. International Journal of Cardiology, 2013, 167, 1101-1108.	0.8	89
92	Interactions of the heart and the liver. European Heart Journal, 2013, 34, 2804-2811.	1.0	346
93	No difference in portal and hepatic venous bacterial <scp>DNA</scp> in patients with cirrhosis undergoing transjugular intrahepatic portosystemic shunt insertion. Liver International, 2013, 33, 1309-1315.	1.9	19
94	Cardiac and renal effects of a transjugular intrahepatic portosystemic shunt in cirrhosis. European Journal of Gastroenterology and Hepatology, 2013, 25, 523-530.	0.8	31
95	Soluble TNF-Alpha-Receptors I Are Prognostic Markers in TIPS-Treated Patients with Cirrhosis and Portal Hypertension. PLoS ONE, 2013, 8, e83341.	1.1	34
96	Cardiac sympathetic imaging with <i>m</i> IBG in cirrhosis and portal hypertension: relation to autonomic and cardiac function. American Journal of Physiology - Renal Physiology, 2012, 303, G1228-G1235.	1.6	23
97	High-sensitivity C-reactive protein levels predict survival and are related to haemodynamics in alcoholic cirrhosis. European Journal of Gastroenterology and Hepatology, 2012, 24, 619-626.	0.8	43
98	Carvedilol or propranolol in portal hypertension? A randomized comparison. Scandinavian Journal of Gastroenterology, 2012, 47, 467-474.	0.6	47
99	Cardiac dysfunction in cirrhosis – does adrenal function play a role? A hypothesis. Liver International, 2012, 32, 1327-1332.	1.9	46
100	Betablockers induce cardiac chronotropic incompetence. Journal of Hepatology, 2012, 56, 298-299.	1.8	23
101	The cardiorenal link in advanced cirrhosis. Medical Hypotheses, 2012, 79, 53-55.	0.8	59
102	Indications for portal pressure measurement in chronic liver disease. Scandinavian Journal of Gastroenterology, 2012, 47, 887-892.	0.6	24
103	Treatment of ascites and spontaneous bacterial peritonitis - part I. Danish Medical Journal, 2012, 59, C4371.	0.5	4
104	Treatment of the hepatorenal syndrome and hyponatremia in cirrhosis - part II. Danish Medical Journal, 2012, 59, C4372.	0.5	1
105	Effects of treatment with β -blocker and aldosterone antagonist on central and peripheral haemodynamics and oxygenation in cirrhosis. European Journal of Gastroenterology and Hepatology, 2011, 23, 334-342.	0.8	4
106	Pitfalls in the assessment of intrapulmonary shunt using lung perfusion scintigraphy in patients with cirrhosis: authors' reply. Liver International, 2011, 31, 139-140.	1.9	0
107	Circulating nitric oxide products do not solely reflect nitric oxide release in cirrhosis and portal hypertension. Liver International, 2011, 31, 1381-1387.	1.9	7
108	Determinants of the hyperdynamic circulation and central hypovolaemia in cirrhosis. Gut, 2011, 60, 1254-1259.	6.1	97

#	ARTICLE	IF	CITATIONS
109	Effects of a single terlipressin administration on cardiac function and perfusion in cirrhosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2010, 22, 1085-1092.	0.8	68
110	Cardiorenal Syndrome – A New Entity?. <i>Frontiers of Gastrointestinal Research</i> , 2010, , 102-111.	0.1	10
111	Effects of a single dose of terlipressin on transcutaneous oxygen pressures. <i>Scandinavian Journal of Gastroenterology</i> , 2010, 45, 953-958.	0.6	6
112	Reduced baroreflex sensitivity and pulmonary dysfunction in alcoholic cirrhosis: effect of hyperoxia. <i>American Journal of Physiology - Renal Physiology</i> , 2010, 299, G784-G790.	1.6	8
113	Cirrhotic cardiomyopathy. <i>Journal of Hepatology</i> , 2010, 53, 179-190.	1.8	278
114	Cardiac and systemic haemodynamic complications of liver cirrhosis. <i>Scandinavian Cardiovascular Journal</i> , 2009, 43, 218-225.	0.4	46
115	Pulmonary dysfunction and hepatopulmonary syndrome in cirrhosis and portal hypertension. <i>Liver International</i> , 2009, 29, 1528-1537.	1.9	35
116	The heart and the liver. <i>Expert Review of Gastroenterology and Hepatology</i> , 2009, 3, 51-64.	1.4	42
117	Ascites: Pathogenesis and therapeutic principles. <i>Scandinavian Journal of Gastroenterology</i> , 2009, 44, 902-911.	0.6	47
118	Efficacy and safety of terlipressin in cirrhotic patients with variceal bleeding or hepatorenal syndrome. <i>Advances in Therapy</i> , 2008, 25, 1105-1140.	1.3	52
119	Pathogenetic background for treatment of ascites and hepatorenal syndrome. <i>Hepatology International</i> , 2008, 2, 416-428.	1.9	47
120	Autonomic dysfunction in cirrhosis and portal hypertension. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2008, 68, 437-447.	0.6	46
121	Effects of terlipressin on the aquaretic system: evidence of antidiuretic effects. <i>American Journal of Physiology - Renal Physiology</i> , 2008, 295, F1295-F1300.	1.3	46
122	Vagal mediation of systemic cardiovascular response to portal hypertension: from experimental studies in animals to treatment of humans. <i>Gut</i> , 2008, 57, 884-885.	6.1	3
123	Reduced baroreflex sensitivity in alcoholic cirrhosis: relations to hemodynamics and humoral systems. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2007, 292, H2966-H2972.	1.5	62
124	Pathophysiological aspects of pulmonary complications of cirrhosis. <i>Scandinavian Journal of Gastroenterology</i> , 2007, 42, 419-427.	0.6	23
125	Diurnal variation and dispersion in QT interval in cirrhosis: Relation to haemodynamic changes. <i>Journal of Hepatology</i> , 2007, 47, 373-380.	1.8	45
126	Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome. <i>Hepatology</i> , 2007, 46, 1863-1871.	3.6	126

#	ARTICLE	IF	CITATIONS
127	Effect of 1,25-dihydroxy-vitamin D ₃ in experimental sepsis. International Journal of Medical Sciences, 2007, 4, 190-195.	1.1	57
128	Determinants of the renin-angiotensin-aldosterone system in cirrhosis with special emphasis on the central blood volume. Scandinavian Journal of Gastroenterology, 2006, 41, 451-458.	0.6	37
129	Meal-induced changes in splanchnic blood flow and oxygen uptake in middle-aged healthy humans. Scandinavian Journal of Gastroenterology, 2006, 41, 87-92.	0.6	43
130	Pulmonary blood volume and transit time in cirrhosis: relation to lung function. Liver International, 2006, 26, 1072-1078.	1.9	10
131	Prognosis in patients with cirrhosis and mild portal hypertension. Scandinavian Journal of Gastroenterology, 2006, 41, 1446-1453.	0.6	7
132	Cardiopulmonary complications in chronic liver disease. World Journal of Gastroenterology, 2006, 12, 526.	1.4	53
133	Pathophysiological basis of pharmacotherapy in the hepatorenal syndrome. Scandinavian Journal of Gastroenterology, 2005, 40, 491-500.	0.6	30
134	Prolonged Q _{Tc} interval in mild portal hypertensive cirrhosis. Journal of Hepatology, 2005, 43, 637-644.	1.8	66
135	Effects of tilting on central hemodynamics and homeostatic mechanisms in cirrhosis. Hepatology, 2004, 40, 811-819.	3.6	28
136	Acute non-selective β_2 -adrenergic blockade reduces prolonged frequency-adjusted Q _{Tc} interval (QTc) in patients with cirrhosis. Journal of Hepatology, 2004, 40, 239-246.	1.8	116
137	Effects of tilting on central hemodynamics and homeostatic mechanisms in cirrhosis. Hepatology, 2004, 40, 811-819.	3.6	7
138	Plasma volume expansion by albumin in cirrhosis. Relation to blood volume distribution, arterial compliance and severity of disease. Journal of Hepatology, 2003, 39, 24-31.	1.8	76
139	Central and noncentral blood volumes in cirrhosis: relationship to anthropometrics and gender. American Journal of Physiology - Renal Physiology, 2003, 284, G970-G979.	1.6	59
140	Outcome of splanchnic blood flow determination in patients with suspected chronic intestinal ischaemia. A retrospective survey. European Journal of Gastroenterology and Hepatology, 2002, 14, 1193-1197.	0.8	6
141	Dyssynchronous electrical and mechanical systole in patients with cirrhosis. Journal of Hepatology, 2002, 36, 513-520.	1.8	109
142	Blood volume distribution in patients with cirrhosis: aspects of the dual-head gamma-camera technique. Journal of Hepatology, 2001, 35, 605-612.	1.8	81
143	Splanchnic and Systemic Haemodynamic Derangement in Decompensated Cirrhosis. Canadian Journal of Gastroenterology & Hepatology, 2001, 15, 94-106.	1.8	46
144	Central and systemic haemodynamic effects of terlipressin in portal hypertensive patients. Liver, 2000, 20, 51-59.	0.1	120

#	ARTICLE	IF	CITATIONS
145	Amiodarone for Rapid Cardioversion of Chronic Atrial Tachyarrhythmia?. Basic and Clinical Pharmacology and Toxicology, 2000, 86, 283-286.	0.0	8
146	Increased circulating leptin in alcoholic cirrhosis: Relation to release and disposal. Hepatology, 1999, 29, 1818-1824.	3.6	92
147	The sympathetic nervous system in liver disease. Journal of Hepatology, 1998, 29, 328-341.	1.8	146
148	Continuous blood pressure monitoring in cirrhosis. Journal of Hepatology, 1997, 27, 284-294.	1.8	23
149	Endothelin-1 and -3 plasma concentrations in patients with cirrhosis: Role of splanchnic and renal passage and liver function. Hepatology, 1995, 21, 735-739.	3.6	101
150	Noninvasive 24-hour ambulatory arterial blood pressure monitoring in cirrhosis. Hepatology, 1995, 22, 88-95.	3.6	76
151	Decreased right heart blood volume determined by magnetic resonance imaging: Evidence of central underfilling in cirrhosis. Hepatology, 1995, 22, 472-478.	3.6	69
152	Endothelin-1 and endothelin-3 in cirrhosis: Relations to systemic and splanchnic haemodynamics. Journal of Hepatology, 1995, 23, 135-144.	1.8	109
153	Assessment of central blood volume in cirrhosis by radionuclide angiography: What does it really mean?. Hepatology, 1994, 20, 1652-1656.	3.6	9
154	Prognostic variables in patients with cirrhosis and oesophageal varices without prior bleeding. Journal of Hepatology, 1994, 21, 940-946.	1.8	86
155	The Systemic Circulation in Cirrhosis. , 0, , 137-155.		16